For example, combining bortezomib with HSP90 inhibition improved survival and delayed disease progression in mouse models, and suppressed tumour growth in multiple myeloma (MM) cell culture [96, 97]. This evidence concerns the gene HSP90AA1 and Miyoshi myopathy.